Ipsen (IPNP) Stock Overview
A biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IPNP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Ipsen S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €154.25 |
| 52 Week High | €164.05 |
| 52 Week Low | €94.35 |
| Beta | 0.34 |
| 1 Month Change | -1.47% |
| 3 Month Change | 28.54% |
| 1 Year Change | 38.71% |
| 3 Year Change | 47.47% |
| 5 Year Change | 126.34% |
| Change since IPO | 655.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| IPNP | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -6.0% | -1.9% | -2.7% |
| 1Y | 38.7% | 17.6% | 15.6% |
Return vs Industry: IPNP exceeded the UK Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: IPNP exceeded the UK Market which returned 15.6% over the past year.
Price Volatility
| IPNP volatility | |
|---|---|
| IPNP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.9% |
Stable Share Price: IPNP's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine IPNP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 5,535 | David Loew | www.ipsen.com |
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis.
Ipsen S.A. Fundamentals Summary
| IPNP fundamental statistics | |
|---|---|
| Market cap | €12.50b |
| Earnings (TTM) | €443.50m |
| Revenue (TTM) | €3.93b |
Is IPNP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPNP income statement (TTM) | |
|---|---|
| Revenue | €3.93b |
| Cost of Revenue | €750.90m |
| Gross Profit | €3.18b |
| Other Expenses | €2.73b |
| Earnings | €443.50m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 16, 2026
| Earnings per share (EPS) | 5.40 |
| Gross Margin | 80.89% |
| Net Profit Margin | 11.29% |
| Debt/Equity Ratio | 19.7% |
How did IPNP perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/20 08:56 |
| End of Day Share Price | 2026/03/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ipsen S.A. is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Yihan Li | Barclays |
| Charles Pitman | Barclays |